Monjuvi, combined with Revlimid and Rituxan, significantly improves progression-free survival in relapsed/refractory follicular lymphoma, as shown in the inMIND trial. The trial reported a median ...

Epkinly, Rituxan, and Revlimid combination reduces disease progression risk by 79% in relapsed/refractory follicular lymphoma patients. The EPCORE FL-1 trial supports global regulatory submissions and ...

As with other drugs, Rituxan Hycela (rituximab/hyaluronidase) can cause side effects, such as nausea and neutropenia. If side effects of Rituxan Hycela become difficult to tolerate, talk with your ...

1. The first biosimilar of Rituxan, called Truxima, was approved for the treatment of adult patients with non-Hodgkin lymphoma. 2. Xospata, which are tablets, treat adult patients who have acute ...